Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595005 | 0.88 | RPS6KB2 (0.46) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL15958680 | 0.87 | RAB9A (0.52) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL13595008 | 0.86 | PGK1 (0.53) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL8381406 | 0.85 | RPS6KB2 (0.43) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL8381274 | 0.85 | ADORA2A (0.45) | RPS6KB2ADORA2AHRH4ADORA1KDM4E | |
| SCHEMBL8381174 | 0.85 | RPS6KB2 (0.72) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL13595011 | 0.84 | RPS6KB2 (0.52) | RPS6KB2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13595006 | 0.84 | RPS6KB2 (0.52) | RPS6KB2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8380340 | 0.84 | ADORA2A (0.50) | RPS6KB2ADORA2AHRH4ADORA1KDM4E | |
| SCHEMBL8381542 | 0.84 | ADORA2A (0.50) | RPS6KB2ADORA2AADORA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8377872-B2 | Non-structural protein-3 (NS-3) protease inhibitors; viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | RPS6KB2 4560/4885ADORA2A 2525/4885HRH4 1530/4885 |
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | CTSC, DPP4, DNPEP | RPS6KB2 4647/4885ADORA2A 4379/4885HRH4 2769/4885 |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ATG4A, CYP4A22, AADAC | RPS6KB2 4417/4885ADORA2A 1794/4885HRH4 1341/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | RPS6KB2 4248/4885ADORA2A 3329/4885HRH4 2192/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | RPS6KB2 4346/4885ADORA2A 4027/4885HRH4 2290/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | RPS6KB2 4346/4885ADORA2A 4027/4885HRH4 2290/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | RPS6KB2 4618/4885ADORA2A 3683/4885HRH4 1627/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | RPS6KB2 4186/4885ADORA2A 3710/4885HRH4 1908/4885 |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | HPN, PRSS1, SERPINB1 | RPS6KB2 4541/4885ADORA2A 3277/4885HRH4 331/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | RPS6KB2 4656/4885ADORA2A 4080/4885HRH4 1840/4885 |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | CTSC, PRSS1, SPINT2 | RPS6KB2 4745/4885ADORA2A 4284/4885HRH4 2669/4885 |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | RPS6KB2 4262/4885ADORA2A 3877/4885HRH4 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.